Life360, Inc. LIF 深 滬
等待開盤 09-10 09:30:00 美东时间
95.94
-7.170
-6.95%
華盛通- 最 高99.29
- 今 開98.22
- 成交量 124.19万股
- 最 低 94.75
- 昨 收 103.11
- 總市值 74.40亿
- 52周最高 103.65
- 市盈率 靜 --
- 換手率 1.60%
- 52周最低 29.62
- 委 比 71.29%
- 總股本 7754.87万
- 歷史最高 103.65
- 量 比 1.29
- 振 幅 4.40%
- 歷史最低 26.00
- 每 手 1
- 風險率 15.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Labrador Iron Ore Royalty declares CAD 0.40 dividend
Labrador Iron Ore Royalty (TSX:LIF:CA) declares CAD 0.40/share quarterly dividend, 33.3% increase from prior dividend of CAD 0.30. Payable Oct. 29; for shareholders of record Sept. 29; ex-div Sept. 29...
今天 04:41
Dollar General rallies after lifting full-year guidance; Dollar Tree and Five Below also gain
Dollar General Corporation (NYSE:DG) jumped in early trading on Thursday after topping Q2 estimates and setting favorable full-year guidance. Sales increased 5.1% year-over-year during the quarter tha...
08-28 19:13
2025年哪家抗衰产品真正有效？权威盘点揭秘全球五大高效抗衰老保健品牌，日常NMN抗衰看这篇就够了
如今，越来越多人开始重视“保持年轻活力”这一健康需求，市面上主打维护身体机能的营养补充品也随之增多。其中，口服NMN作为一种国际科研界公认的明星抗衰老成分，凭借...
08-27 17:43
如何选对NMN产品？2025年全球抗衰老产品口碑TOP10权威评测：NMN抗衰保健品功效对比与性价比综合研究
时间或许从不停歇，但现代科学已经让我们拥有了延缓其脚步的可能。2025年的抗衰市场呈现出前所未有的技术多样性：从精准激活长寿蛋白的纳米级配方，到多靶点协同作用的...
08-26 16:35
Life360 Launches No Show Alerts to Ease Parents’ Back-To-School Scheduling Stress
Life360 introduces 'No Show Alerts,' a new feature designed to help parents monitor family schedules without constant checking. The feature sends notifications only if a family member doesn't arrive at a designated location by a specified time. This tool addresses the back-to-school chaos, with 53% of surveyed parents citing schedule management as a major stressor. No Show Alerts offers a customizable solution to reduce distractions and keep fami...
08-20 15:00
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Elicio Therapeutics Publishes Follow-Up Data From Phase 1 AMPLIFY-201 Study In Nature Medicine
At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS")
08-12 20:11
Stifel Maintains Buy on Life360, Raises Price Target to $92
Stifel analyst Mark Kelley maintains Life360 (NASDAQ:LIF) with a Buy and raises the price target from $87 to $92.
08-12 19:14
CORRECTION: Life360 Q2 EPS $0.08 Beats $(0.01) Estimate, Sales $115.400M Beat $109.686M Estimate
Life360 (NASDAQ:LIF) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.01) by 766.67 percent. This is a 153.33 percent increase over losses of $(0.15) per share from the same
08-12 05:45
Life360 Raises FY2025 Sales Guidance from $450.000M-$480.000M to $462.000M-$482.000M vs $469.657M Est
Life360 (NASDAQ:LIF) raises FY2025 sales outlook from $450.000 million-$480.000 million to $462.000 million-$482.000 million vs $469.657 million estimate.
08-12 04:38
